The peripheral blood was collected from 104 breast cancer patients（breast cancer group）， 52 benign breast disease patients（benign breast disease group） and 50 healthy individuals（healthy control group）， and the expression levels of hMAM， SBEM and CEACAM19 mRAN in peripheral blood nucleated cells were detected by real-time fluorescence quantitative PCR（RT-qPCR） method； the positive expression rates were calculated and their relationships with patients’ clinicopathologic features were analyzed.

In breast cancer group， the positive expression rates of SBEM and CEACAM19 mRNA in peripheral blood were associated with lymph node metastasis （P<0.05）， the positive expression rate of CEACAM19 mRNA was associated with estrogen receptor（ER） expression （P<0.05）， and the positive expression rate of hMAM mRNA was associated with human epidermal growth factor receptor-2（HER-2） expression（P<0.05）. The positive expression rates of hMAM mRNA in peripheral blood in breast cancer group were significantly increased compared with healthy control group and benign breast disease group（P<0.05）， both alone and in combined with SBEM and CEACAM19. The positive expression rate of hMAM mRNA was increased from 39.4% to 66.3% by combined detection of the three indicators. The positive expression rates of hMAM mRNA in peripheral blood of the breast cancer patients at TNM stage Ⅲ+Ⅳ were higher than those of patients at TNM stage Ⅰ+Ⅱ（P<0.01）， both alone and in combined with SBEM and CEACAM19. By combined detection of hMAM，SBEM， andCEACAM19 mRNA， the positive expression rate of hMAM mRNA in peripheral blood of the breast cancer patients at TNM stage Ⅰ+Ⅱwas increased from 20.40% to 48.98% and at TNM stage Ⅲ+Ⅳ from 56.40% to 81.82%.

The positive expression rate of hMAM mRNA in peripheral blood of the breast cancer patients is not high. Combined detection of SBEM and CEACAM19 mRNA can increase the positive expression rate， which has certain clinical significance in the diagnosis of breast cancer.